Inflammatory Marker Testing Identifies CD74 Expression in Melanoma Tumor Cells, and Its Expression Associates with Favorable Survival for Stage III Melanoma
Sühendan Ekmekçioglu(The University of Texas MD Anderson Cancer Center), Elizabeth A. Grimm(The University of Texas MD Anderson Cancer Center), Roland L. Bassett(The University of Texas MD Anderson Cancer Center), Dave S.�B. Hoon(Saint John's Health Center), Jason Roszik(The University of Texas MD Anderson Cancer Center), Myung Shin-Sim(Saint John's Health Center), Michael A. Davies(The University of Texas MD Anderson Cancer Center), Jeffrey E. Gershenwald(The University of Texas MD Anderson Cancer Center), Víctor G. Prieto(The University of Texas MD Anderson Cancer Center), Donald L. Morton(University of California, Los Angeles), Scott E. Woodman(The University of Texas MD Anderson Cancer Center), Denái R. Milton(Cancer Research And Biostatistics), Keiji Tanese(Toho University)
Cited by 51
Related Papers
Completion Dissection or Observation for Sentinel-Node Metastasis in Melanoma
|New England Journal of Medicine|2017|1.4k
Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial
|The Lancet Oncology|2012|906
Dietary fiber and probiotics influence the gut microbiome and melanoma immunotherapy response
|Science|2021|876
Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumab
|Annals of Oncology|2016|822
Guidelines of care for the management of primary cutaneous melanoma
|Journal of the American Academy of Dermatology|2018|707